Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Engineering Clinical Trials 142

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study. Sanofi, Empowering Life.

Immune Response 52

Immune Response Vaccine Trials Treatment 52

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. Engineering adeno-associated virus vectors for gene therapy.

Engineering 105

Engineering Virus Therapies Immune Response 105

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

PerkinElmer

JANUARY 25, 2023

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. Experts in the diagnostics and life sciences industry look back on 2022 and lend their insights on the major trends and technologies shaping laboratories in 2023.

Science 52

Science Laboratories Immune Response Disease 52

The Pharma Data

AUGUST 27, 2020

SCIENCE PHOTO LIBRARY. A new effort is under way to understand how the immune system responds to coronavirus. Scientists from 17 UK research centres are attempting to answer questions such as how long immunity lasts and why disease severity varies so much. Coronavirus immunity: Can you catch it twice? Image copyright.

Immune Response 52

Immune Response Virus Vaccine Disease 52

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

Codon

SEPTEMBER 29, 2024

While mRNA data was often illuminating, their interpretation was tricky; more akin to art than science. Models of life became the dominant research paradigm in nearly every life-sciences field. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within.

Engineering 131

Engineering Virus DNA Therapies 131

The Pharma Data

NOVEMBER 27, 2020

UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Iceni Diagnostics has revealed it is developing a new technology that can disclose if patients are actually infectious with a live virus or not.

Vaccine 52

Vaccine Virus International Immune Response 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 116

Therapies Virus DNA Clinical Trials 116

The Pharma Data

JANUARY 31, 2021

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. About Gilead Sciences. Gilead Sciences, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

SEPTEMBER 14, 2020

Science Photo Library. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus. Antibodies could be described as the “warriors” of the immune system. Image copyright. Image caption.

Trials 52

Trials Immune Response Virus Vaccine 52

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms. Paper Cited Liu B, Carlson R, et al. Human STING is a proton channel. Online August 3, 2023. DOI :10.1126/science.adf8974.

Regulations 91

Regulations Clinical Trials Engineering DNA 91

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Broad Institute

AUGUST 11, 2022

The study appears in Science. In the new study, they homed in on a handful of these genes encoding enzymes that are members of the STAND ATPase family of proteins, which in eukaryotes are involved in the innate immune response. The cells underwent a dramatic defensive response and survived.

DNA 52

DNA Virus Immune Response Bioinformatics 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Immune Response 52

Immune Response Virus Disease Doctors 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. Credit: DE Gordon et al.,

Drug Development 52

Drug Development Drugs Virus Science 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases. 2021;22(6):2922.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes.

Vaccine 52

Vaccine Virus Research Immune Response 52

Codon

DECEMBER 12, 2024

” The report accompanies an article in Science , also released today, entitled “Confronting Risks of Mirror Life.” It would also be undetectable by key parts of the human immune system. ” But what, exactly, is a mirrored organism? To answer that, let’s consider how extant life works.

RNA 99

RNA DNA Vaccine Virus 99

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

MAY 27, 2022

The authorisation is based on a review by the Committee for Medicinal Products for Human Use (CHMP) of the substantial body of evidence demonstrating an increased immune response after a third dose booster with Vaxzevria following a primary vaccine schedule of either Vaxzevria or an mRNA COVID-19 vaccine.(1-5). About AstraZeneca.

Vaccine 52

Vaccine Virus Immune Response Licensing 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. References : [1] Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. In the U.S. medRxiv.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

SEPTEMBER 2, 2021

Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness. 2,3 The virus is highly contagious and affects the lungs and airways. RSV is a significant cause of severe respiratory disease in older adults, and it can cause disability and death. Burden of RSV. About RSVpreF.

Clinical Trials 52

Clinical Trials Trials Vaccine Virus 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. The research was published online recently in Proceedings of the National Academy of Sciences.

Immune Response 52

Immune Response Virus Engineering Disease 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. It’s one reason why science has yet to come up with a cure for the common cold. FRIDAY, Dec. regulators.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JANUARY 11, 2021

Pfizer and BioNTech reported that their COVID-19 vaccine appears to be effective against a key mutation in new variants of the SARS-CoV-2 virus that causes COVID-19. Gilead Sciences ’ Veklury, which is better known by its scientific name remdesivir, is the only antiviral drug currently approved to treat COVID-19. and now 501.V2,

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

DECEMBER 31, 2020

But painstaking work by Australian researchers has revealed that people infected with the SARS-CoV-2 virus have immune memory to protect against reinfection for at least eight months. “Because of the biology of the persistence of these memory cells, it anticipates that we will have rather durable immunity,” said Dr. .

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. GSK’s response to COVID-19 has been one of the broadest in the industry, with two potential treatments in addition to our vaccine candidates in development. GSK commitment to tackling COVID-19.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

Drug Target Review

SEPTEMBER 8, 2023

The study’s outcomes are also the fruit of a fruitful collaboration involving scientists from the RIKEN Center for Integrative Medical Sciences in Japan, alongside local research teams from UC San Diego and the Salk Institute. This led her lab to conduct a more thorough examination of retinoic acid receptors, including RARα.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. The test targets antibodies against the spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

JANUARY 11, 2021

The study from China involved more than 1,700 patients first diagnosed with the virus in Wuhan between January and May, and then followed to June and September. That finding increases concern about the possibility of survivors being reinfected by the virus. MONDAY, Jan. His team published the findings in The Lancet journal Jan.

Hospitals 52

Hospitals Virus Vaccine Immune Response 52

The Pharma Data

JANUARY 3, 2021

. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. Patient reported outcome to assess clinical responses related to COVID-19 symptoms, as per the FDA guidelines, will also be collected. About Tiziana Life Sciences. .

Clinical Trials 40

Clinical Trials Science Treatment Trials 40